180 results about "Blood concentration" patented technology

The invention belongs to the field of pharmaceutical preparations, and relates to a brexpiprazole long-acting microsphere and a preparation method thereof, and the preparation method comprises the following steps: (1) dissolving brexpiprazole and a degradable polymer in an organic solvent to obtain a drug-containing polymer solution as an oil phase; (2) mixing the drug-containing polymer solution with a polyvinyl alcohol solution through a microfluidic technology to obtain an oil-in-water emulsion; and (3) under a stirring condition, carrying out curing, washing and freeze drying on the oil-in-water type emulsion to obtain the brexpiprazole long-acting microspheres. By adjusting the volatilization stirring time when the O / W primary emulsion is formed, the final in-vitro release rate of the microspheres is adjusted, and the microspheres which are free of burst release and hysteresis period and are slowly released can be screened out. The brexpiprazole long-acting microsphere provided by the invention is simple in preparation process, easy to industrially amplify, high in encapsulation efficiency, large in drug loading capacity, uniform in microsphere particle size distribution, round in shape, good in flowability and good in needle passing property, is easier to inject, has an obvious slow release effect, and can be used for reducing the fluctuation of blood concentration and effectively improving the compliance of psychiatric patients.

The invention discloses a method for detecting the concentration of cyclosporine in blood through fluorescence and electrochemical double signals, and belongs to the technical field of biochemical analysis and medical detection. Aiming at the technical problems of insufficient sensitivity and high false positive rate of traditional single-signal detection of blood concentration of cyclosporine, the method comprises the following steps: activating carboxyl microspheres by a coupling agent, fixing double-stranded DNA (deoxyribonucleic acid) formed by a cyclosporine aptamer and an initiator chain, inducing the initiator to release by using a cyclosporine sample, realizing strand displacement through an A2-PEI composite system, and detecting the blood concentration of cyclosporine by using an A < 2 >-PEI composite system. DNA modified cadmium telluride quantum dots are respectively adopted to detect fluorescence signals, eATRP electrochemical signal amplification is carried out to detect electrochemical signals, concentration values obtained by the two signals are verified, and an average value is taken as a result. The method can accurately capture low-concentration cyclosporine signals in blood, eliminates interference of a single method, is mainly used for accurately monitoring the blood concentration of cyclosporine, and provides a reliable detection means for medication safety and curative effect control of cyclosporine in clinical scenes such as organ transplantation.

The invention relates to a self-management behavior auxiliary system for gestation and epilepsy patients, and belongs to the technical field of medical monitoring and diagnosis. The auxiliary system comprises a detection unit used for obtaining physiological parameters, related to pregnancy combined epilepsy, of a patient; the processing unit is used for analyzing and processing the data obtained by the detection unit so as to evaluate the health trend of the patient, and the physiological parameters obtained by the detection unit comprise the blood concentration, the liver enzyme activity and the blood sugar level. The processing unit can calculate and obtain a gestational epilepsy management index used for representing the health trend of the patient based on the physiological parameters so as to judge the epilepsy risk condition of the patient in the current gestational period.

The invention discloses a construction method of a rivaroxaban population pharmacokinetic model and application of the rivaroxaban population pharmacokinetic model in an individualized medication prediction model, and relates to the field of biological information. According to the invention, a high performance liquid chromatography-tandem mass spectrometry method is adopted to determine the blood concentration of a rivaroxaban taking person, and a DNA sequencing method is adopted to determine the gene polymorphism of related metabolic enzymes CYP3A4 and CYP3A5 and transporters ABCB1 and ABCG2 of the rivaroxaban taking person; collecting data to establish a rivaroxaban group pharmacokinetic model, performing internal verification, and evaluating the stability and prediction performance of the model; in the final PPK model, the influence of the creatinine clearance rate, the ABCB1rs1045642 and the health condition on the clearance rate is the greatest; the experimental verification result shows that the model has good predictability and is accurate and reliable; the method can be applied to an individualized medication prediction model.

The invention provides a penicillamine sustained-release preparation. The release rate of the penicillamine sustained-release preparation is adjusted through a specific sustained-release coating. Unexpectedly, the release rate can be obviously improved by adding a small amount of lactose. More unexpectedly, in the prescription system provided by the invention, under the condition that the weight gain of the sustained-release coating is the same, the penicillamine sustained-release preparation which can be released for 12 hours or 24 hours can be respectively obtained only by adjusting the content of lactose, that is, the release rate of the penicillamine sustained-release preparation in 12 hours or 24 hours can reach 85% respectively. According to the penicillamine sustained release preparation provided by the invention, the medication compliance can be improved, and the blood concentration fluctuation can be reduced.

The invention discloses a gastric retention double-layer sustained-release tablet and a preparation method and application thereof, and belongs to the field of pharmaceutical preparations, the active ingredient of the gastric retention double-layer sustained-release tablet is 3-[4-[4-(lH-benzotriazole-1-yl) butyl] piperazine-1-yl] benzisothiazole hydrochloride, and the gastric retention double-layer sustained-release tablet is composed of a quick-release drug release layer and a sustained-release drug release layer, the quick release layer contains an active component, a filler I and a disintegrating agent; and the sustained-release layer contains an active component, a filler II, an expansion material, a release retardant, an expansion accelerator and a stabilizer. According to the gastro-retention double-layer sustained-release tablet, the quick-release layer can quickly release the medicine to reach the effective blood concentration, and the retention time of the tablet in the stomach is prolonged after the sustained-release layer expands, so that the in-vivo absorption window of the medicine is prolonged, the maintenance of the blood concentration is realized, the in-vivo half-life period of active ingredients is remarkably prolonged, the administration frequency can be reduced, and the compliance of a patient is improved. The product is simple in preparation process, suitable for industrial production and wide in development prospect.

To provide an estimation method of a recirculation rate enabling estimation of a recirculation rate without being limited by a preparation location of a blood marker or an arrangement location of detection means of the blood marker.SOLUTION: An estimation method of a recirculation rate includes the steps of: acquiring data representing an amount of change in blood concentration after recirculation when a blood marker is added to blood to be extracorporeally circulated, data representing a relation between an amount of change in blood concentration after recirculation and blood concentration, and data representing a relation between the amount of change in blood concentration after recirculation and a blood flow rate; creating a model by multivariate analysis or machine learning to obtain a regression equation or a conversion model, with the amount of change in blood concentration after recirculation, blood concentration and a blood flow rate used as an explanatory variables and the recirculation rate as an objective variable; acquiring data representing the amount of change in blood concentration, blood concentration and a blood flow rate of blood flowing through an arterial line or a venous line; and inputting treatment data to the regression equation or the conversion model to estimate the recirculation rate.SELECTED DRAWING: Figure 3A

To provide a method and device for predicting plasma concentration transition in combination of multiple drugs, by easily determining Ki, fm in vivo, and making them into a database, since, there has been dynamic prediction using a physiologic medicine speed theory (PBPK) model, as a prediction method of a drug interaction for medical products, however, prediction using an inhibition constant (Ki) of in vitro data and a contribution ratio (fm) of a metabolic enzyme, do not always match increase of clinical AUC.SOLUTION: There is provided a method for determining a parameter of a compartment model from a pharmacokinetic parameter of an interacted drug and interaction drug, then converting the compartment parameter into a PBPK model parameter, then determining by simulation using the PBPK model, a Ki value and fm being AUC increase ratios observed clinically. The acquired parameter is made into a database, and simulation of blood concentration transition of the interacted drug and interaction drug is performed.SELECTED DRAWING: Figure 1

The invention provides a construction method of a PPK model of r-ATG used by children and a determination method of a drug administration scheme. The construction method comprises the following steps: acquiring statistical characteristics of a plurality of child patients; r-ATG instillation is conducted on the multiple child patients according to a preset administration plan, blood sample collection is conducted on the multiple child patients according to a preset sampling plan, and blood concentration data of the multiple child patients are obtained; dividing the blood concentration data of the child patients into model construction group data and model verification group data, and constructing an initial PPK model based on the statistical characteristics and the model construction group data; performing internal verification on the initial PPK model based on the model verification group data to obtain an internal verification result, and performing external verification on the initial PPK model based on the model verification group data to obtain an external verification result; and correcting the initial PPK model according to the internal verification result and the external verification result to obtain a target PPK model. The method can improve the safety of r-ATG administration for children.

The invention relates to pamoate drug sustained release microspheres and a preparation method thereof. According to the sustained-release microsphere preparation for injection prepared by the preparation method disclosed by the invention, the particle size distribution of the microspheres is relatively narrow, and the release time of active pharmaceutical ingredients can last for about three months to four months. Besides, the microsphere preparation prepared by the invention can maintain stable blood concentration in an animal body, has no large fluctuation of the blood concentration within 3-4 months, and better avoids the occurrence of toxic and side effects.

The invention discloses a hydrogel microsphere with a core-shell structure, the hydrogel microsphere comprises a sodium hyaluronate hydrogel core and a sodium alginate shell, and the sodium hyaluronate hydrogel core also comprises a slow release factor and divalent metal ions. The hydrogel microspheres with the sodium hyaluronate hydrogel as the inner core and the alginic acid as the shell can realize accurate targeted blasting in the intestinal tract, and can be adhered to the local part of the intestinal wall to induce benign intestinal flora to treat the inflammatory bowel disease, so that the phenomenon that when the medicine arrives at the intestinal tract, the medicine cannot be damaged is avoided; due to peristalsis of the intestinal tract, the medicine can not be accurately released to a specific position. The mass ratio of sodium hyaluronate to sodium alginate is controlled to be (4-20): 1, and the explosion speed of the microspheres is controlled, so that the release speed and the position accuracy of the medicine are controlled, the problem that the blood concentration of the medicine cannot be effectively controlled due to the fact that the release speed of the medicine is too high or too low is solved, the curative effect of the medicine is improved, and side effects are reduced.

The invention relates to the technical field of medical instruments, and discloses a dynamic blood glucose monitoring system after kidney transplantation based on artificial intelligence, the system comprises a data acquisition and transmission module, an AI decision support module, a risk early warning and report generation module, a feedback and optimization module and a system integration module; an AI drug disturbance analysis module is arranged, when postoperation blood glucose is monitored in real time, an immunosuppressor-blood glucose dynamic response model is established, the causal relationship between the blood concentration of a specific drug and glucose metabolism is analyzed, and a drug correlation event label is labeled in real time; by means of the method, whether blood glucose fluctuation is triggered by immunosuppressor metabolism abnormality or not can be accurately recognized, it is avoided that drug-induced hyperglycemia is misjudged as an dietary event, the accuracy of treatment intervention decision making is guaranteed, and the rejection risk is reduced.

The invention provides a method for detecting the blood concentration of elacycline in serum. The method comprises the following steps: pretreating a human serum sample; then detecting by adopting liquid chromatography-mass spectrometry, wherein a liquid chromatography condition mobile phase comprises ultrapure water (a mobile phase A) containing 0.1% of formic acid and acetonitrile (a mobile phase B); the temperature of the chromatographic column is kept at 45 DEG C, and the sample size is 2L; the flow velocity of the mobile phase is set to be 0.3 mL / min, and the total operation time is 4.5 minutes; in mass spectrum conditions, a positive electrospray ionization mode is adopted, multiple reaction monitoring (MRM) is adopted, and multi-reaction monitoring is adopted as a scanning mode. The method is high in sensitivity, the lowest quantitative concentration can reach 50 ng / mL, and accurate, rapid and sensitive determination of the elacycline in the human serum can be realized.

The invention discloses a topiromilast osmotic pump tablet and a preparation method thereof. The topiromilast osmotic pump tablet comprises a tablet core composed of a drug layer and a pushing layer, a semipermeable membrane coating outside the tablet core, and a single drug release small hole and an isolation coating on the surface of a controlled release tablet on one side of the drug layer. Compared with topiromilast tablets on the market at present, the topiromilast osmotic pump controlled release tablet prepared by the invention can realize continuous and stable constant-speed release of drugs. After a patient takes the medicine, the medicine in the medicine release layer cannot be released immediately, and the tablet can rhythmically release the medicine, maintain the steady-state blood concentration, delay the peak time and prolong the half-life period of the medicine within more than ten subsequent hours under the action of the pushing layer, so that the bioavailability is improved, and the slow release effect of more than 12 hours is achieved. Due to the adoption of a double-layer osmotic pump controlled release technology, compared with a single-layer tablet, the double-layer osmotic pump controlled release tablet has the advantages of stronger controllability, more complete release and higher availability.

The invention provides a loxoprofen sodium double-release capsule micro-tablet and a preparation method of the loxoprofen sodium double-release capsule micro-tablet. Through the synergistic effect of the quick-release micro-tablet and the sustained-release micro-tablet, the quick-release micro-tablet can realize quick release and absorption, and the sustained-release micro-tablet can maintain relatively stable blood concentration for a long time. The administration frequency is reduced, the coordination of the postprandial administration requirement and the dietary habit is ensured, and the occurrence of gastrointestinal tract adverse reactions is reduced. The preparation provided by the invention conforms to the dosage form design of the hour pharmacology, can quickly take effect through administration twice every day, can maintain the blood concentration in the high-incidence time period of night diseases, avoids the disadvantage of taking medicine after meal when the night diseases attack, guarantees the sleep quality, and improves the overall treatment effect. The micro tablet is small in size and easy to swallow, and the medication compliance of patients with dysphagia is obviously improved. Through dosage form design and improvement, unmet clinical requirements are expected to be met by virtue of obvious advantages of the traditional Chinese medicine composition.

The present application relates to the technical field of federated learning, and particularly to a blood drug concentration anomaly analysis method based on federated learning, comprising the following steps: a center server generates and issues a proxy data set without privacy risk to a plurality of medical institution clients; and receiving local prediction logits generated and uploaded by the plurality of medical institution clients after predicting the proxy data set by using local heterogeneous models. In the present application, a dynamically evolving global prototype memory bank is combined for anomaly judgment, a normal prototype benchmark reflecting the latest global state is constructed by periodically fusing feature distributions extracted by each node at different time stages, so that anomaly detection no longer depends on static or isolated rules, but is based on a dynamically updated and collectively agreed dynamic standard, thereby improving the robustness and accuracy of anomaly judgment.

The invention discloses traditional Chinese medicine granules with an auxiliary blood pressure lowering effect and a preparation method thereof. The traditional Chinese medicine granules are prepared by mixing uncaria, scutellaria baicalensis, semen cassiae, the root of kudzu vine, selfheal, leonurus, gastrodia elata, microcrystalline cellulose and a ginseng essential oil slow-release agent and then carrying out granulation and freeze-drying processes. Wherein the ginseng essential oil sustained-release agent is prepared by adopting ginseng essential oil and Tween 80 to form a nano microemulsion, then wrapping the nano microemulsion in a chitosan and sodium linoleate compound coating solution and performing freeze drying, and the ginseng essential oil sustained-release agent prepared in the mode can effectively prevent the ginseng essential oil from being in contact with oxygen to cause an oxidation phenomenon; the core functions of the ginseng essential oil sustained-release preparation are to control the release rate of active ingredients, reduce the administration frequency, maintain more stable blood concentration or active ingredient level, prolong the retention time of the medicine in gastrointestinal tracts, further promote absorption and improve the bioavailability.

The present application relates to an extracorporeal blood treatment system (50) for treating a subject, the system comprising: an extracorporeal blood circuit (52); a dialysate fluid circuit (54); the extracorporeal blood circuit and the dialysate fluid circuit being separated by a membrane (56) of a filtration unit (58); at least one blood pump (60) for controlling the flow of blood through the blood circuit; at least one dialysate fluid pump (62) for controlling the flow of dialysate fluid through the dialysate fluid circuit (54); a system computing unit (64) operatively connected to the blood pump and to the dialysate fluid pump, the system computing unit having at least one input; wherein the system computing unit is adapted to receive a desired blood concentration of glutamine GLN b , to receive a desired blood concentration of glucose GLUCOSE b , and to receive a desired blood concentration of ketone bodies KETONE b ; the system computing unit being adapted to control the blood pump and the dialysate fluid pump such that an actual concentration value of glutamine GLN a is driven to approach GLN b , and an actual concentration value of glucose GLUCOSE a is driven to approach D b , and an actual concentration value of ketone bodies is driven to approach KETONE a . The present application relates to a treatment device for use in an extracorporeal blood treatment system, a method for treating cancer using the system, a controller for controlling the method and a dialysis liquid suitable for use in the method.

The invention relates to the technical field of medical examination, and discloses a method for rapidly measuring the blood concentration of posaconazole and application of the method. According to the method for rapidly determining the blood concentration of posaconazole and the application of the method, compared with chromatography in the prior art, the adopted mobile phase is relatively single, the configuration time of the mobile phase is saved, and meanwhile, the fluctuation of a detection result caused by the configuration of the mobile phase is reduced to the greatest extent; the stability of the method is further enhanced; meanwhile, compared with other liquid chromatography methods, the detection method has the advantages that the single-needle sample injection time is short, the reagent preparation is simple, no endogenous and common exogenous substance interference exists around the target peak of posaconazole, and the like, and the detection efficiency and the accuracy of the detection result are improved.

The invention relates to a riociguat prodrug as shown in a formula X or pharmaceutically acceptable salt thereof, a preparation method, an intermediate and a pharmaceutical composition thereof. The prodrug takes amino of riociguat as a modification site and is connected through an ester carrier, drug release is triggered by utilizing lung amidase, and lung targeted delivery is realized by adjusting a lipid-water partition coefficient. Pharmacokinetic studies show that the prodrug can significantly improve the drug concentration and total exposure of the lung, reduce the blood concentration of the whole body, and show excellent lung targeting characteristics. The invention also provides a pharmaceutical composition (preferably an inhalation preparation) containing the prodrug, and an application of the prodrug in preparation of drugs for preventing, treating, treating or relieving pulmonary arterial hypertension of patients. .

This application relates to a preparation method of a protective three-dimensional structured hemostatic textile spacer fabric, and relates to the field of knitted medical dressings. In this application, the spacer dressing uses carboxymethyl-modified viscose filament-PTFE braided yarn as the skin contact material, and quickly stops bleeding through three methods: physical, chemical, and biological. The physical principle is to absorb blood to form a gel-like substance to block the wound. The chemical action concentrates the blood concentration to activate the coagulation system. The biological action releases negative ions to activate coagulation factors and initiate the endogenous coagulation system. Sodium carboxymethyl cellulose can be obtained by carboxymethylation modification of fibers, and PTFE plays a structural support role; Coolmax-nylon monofilament wrapping yarn with high water absorption and elastic recovery is used as the spacer filament; ultra-high molecular weight polyethylene fiber with superhydrophobicity is used as the outer surface material, and the surface structure is tight to play a barrier role; furthermore, a preparation method of a protective three-dimensional structured hemostatic textile spacer fabric is designed.

The invention belongs to the technical field of biological medicine, and particularly relates to a ganoderma lucidum polysaccharide sustained-release liver protection preparation and a preparation method thereof.The preparation comprises a pellet, the pellet comprises a pellet core, a medicine layer, an inner sustained-release layer and an outer mucous membrane attachment enteric-coated composite layer, and the pellet core is coated with the medicine layer, the inner sustained-release layer and the outer mucous membrane attachment enteric-coated composite layer in sequence; the medicine layer contains high-purity ganoderma lucidum polysaccharide; the inner slow-release layer is composed of ethyl cellulose, triethyl citrate and polyethylene glycol 4000; the outer mucous membrane attachment enteric composite layer is formed by compounding chitosan and a pH sensitive polymer, preferably, an in-situ network structure is formed through calcium ion crosslinking, and the outer mucous membrane attachment enteric composite layer has the enteric function and the mucous membrane attachment function. The invention aims to solve the problems that the existing ganoderan preparation is too fast in release, large in blood concentration fluctuation and short in action time. Through the synergistic effect of the structures, the ganoderma lucidum polysaccharide sustained-release liver protection preparation is stable in stomach, targeted in intestinal tract release and retained in mucous membranes, the sustained-release effect of 12 h or above is achieved, and the bioavailability and the liver protection curative effect are remarkably improved.

The present invention relates to a multiple controlled-release tablet composition of ruxolitinib or a pharmaceutically acceptable salt thereof, which is useful for treating Janus kinase-associated diseases such as myeloproliferative disorders, and a method for producing the same. More specifically, the present invention relates to a multiple controlled-release tablet composition and a method for producing the same, which exhibits a maximum drug blood concentration similar to that of commercially available immediate-release formulations, while controlling the drug release rate so as to efficiently maintain the drug at or above the effective blood concentration in the body, thereby enabling once-daily administration, unlike commercially available formulations that are administered twice daily.

To provide a novel material or composition that is effective in preventing or alleviating dyslipidemia. [Solution] A material or composition containing live or dead yeast cells or yeast hydrolysates for preventing or alleviating dyslipidemia. Dyslipidemia here refers to one or more abnormalities in blood concentrations of LDL cholesterol (bad cholesterol), HDL cholesterol (good cholesterol), and triglycerides (neutral fats). Zygosaccharomyces rouxii or Pichia are preferred as the yeast. The yeast is preferably of food origin and preferably intended for human consumption.

The embodiment of the present application provides a medical detection device, comprising: a shell; a pressure measuring component, which is installed on the outer wall of the shell and is used for measuring the pressure of the environment outside the shell; and a concentration measuring component, which is installed on the outer wall of the shell and is used for measuring the concentration of a parameter to be measured in the environment outside the shell. The medical detection device in the embodiment of the present application can realize the detection of various parameters (including pH value, occult blood concentration, pepsin concentration and trypsin concentration) in the digestive tract, thereby improving the accuracy of the detection result of the medical detection device on the digestive tract. Meanwhile, the medical detection device can realize the measurement of the pressure in the digestive tract, thereby further improving the accuracy of the detection result. Moreover, the medical detection device can reduce the medical detection procedure and the number of devices required in the detection process, thereby saving the cost.

The invention relates to a preparation method and application of a suvortinib standard substance in human serum, and belongs to the field of medical examination. The standard substance is characterized by comprising the following three levels of suvaltinib solutions: a level 1: 10.00-50.00 [mu] g / L, a level 2: 10.00-50.00 [mu] g / L, and a level 3: 10.00-50.00 [mu] g / L; the level 2 is 450.00 to 750.00 [mu] g / L; the level is 3: 1200.00 to 2000.00 [mu] g / L; wherein the level 1 corresponds to the concentration range of the blood concentration trough of the suvortinib in the serum of a patient taking the medicine; the level 2 is an effective treatment blood concentration range; and the level 3 is the peak concentration range of the blood concentration. The standard substance can be used as a conventional detection limit and a reportable range of suvortinib in human serum. The standard substance has good uniformity, stability and interoperability, and can be applied to the fields of accuracy evaluation of blood concentration detection, detection result value traceability, performance evaluation of medical equipment, instrument calibration, research and development of medical equipment and the like.

The present disclosure provides nanoparticle transducers and methods of use thereof for the detection of analyte concentrations in a fluid. Nanoparticle transducers can comprise a nanoparticle, such as a Pdot, coupled to an enzyme that catalyzes a reaction with the analyte. The nanoparticle transducers further comprise chromophores that emit fluorescence that varies as a function of the concentration of one of the elements of the reaction. The nanoparticle transducer thus changes fluorescence as the analyte concentration changes, transforming analyte concentration values into fluorescence intensities. The measurement of these intensities provides a measurement of the analyte concentration. The nanoparticle transducers are biocompatible, allowing for use in vivo, for the monitoring of analyte blood concentrations such as blood glucose concentrations.

The present invention belongs to the field of detection of mycophenolic acid blood drug concentration, and specifically relates to a method for quantitatively detecting mycophenolic acid in trace blood by high performance liquid chromatography-tandem mass spectrometry, which comprises the following steps: after adding an internal standard solution to the plasma sample to be tested, adding a mixed solution of KH2PO4 and EDTA, the pH value of the mixed solution is 8-9, and mixing evenly; adding a propionic anhydride solution to the evenly mixed system, oscillating and reacting, centrifuging, and taking the supernatant for LC-MS / MS detection. Mycophenolic acid has a phenolic hydroxyl group, and under certain pH value and temperature, it undergoes an esterification reaction with propionic anhydride, and the derivative product is [M + CH3CH2CO] + peak, which simultaneously solves the problem that the sample volume is too low to affect the sensitivity, and reduces the interference of other substances.

The invention relates to the technical field of drug release adjustment, and particularly discloses a drug release adjustment method and system based on sweat pH value and temperature, and the method comprises the steps: S1, obtaining sweat pH value and skin surface temperature information of a region, and obtaining a signal A and a signal B respectively; s2, preprocessing to obtain a stabilized signal; s3, calculating an instantaneous drug release rate, and quantifying to obtain a current nano preparation release efficiency coefficient; S4, driving a microneedle channel to open and control to obtain a blood concentration; s5, sampling and detecting the released blood concentration to obtain a feedback concentration signal; s6, updating the release efficiency coefficient to obtain a nano preparation release efficiency coefficient of a new period; dual signals of sweat pH and skin surface temperature are synchronously collected, stable input is generated after pretreatment, subtle changes of body surface and in-vivo physiological states can be reflected in real time, and therefore richer and more reliable basis is provided for drug release decision, and drug delivery precision is effectively improved.

The utility model discloses a urination observation device, which relates to the related technical field of medical instruments and comprises a mounting shell, the rear side of the mounting shell is detachably connected with a clamping plate, the upper end of the mounting shell is fixedly communicated with a liquid inlet pipe, and the upper side of the interior of the mounting shell is fixedly connected with a partition plate. A storage cylinder is detachably connected to the left side of the interior of the mounting shell, and a guide valve is rotationally connected to the surface of the storage cylinder; the urine is collected by adopting the storage cylinder, the concentration of the urine at the bottom of the storage cylinder is higher under the action of standing and stacking at the moment, then the urine enters the reaction box through the hose and chemically reacts with peroxidase, and when the reacted urine drips on the color card, the color card is separated from the color card. Whether the current urine contains blood or not and the blood concentration are judged according to the color of the urine on the color card, so that medical staff can know the urine condition of a current patient more clearly and visually.